Treatment Subgroups (Male) Treatment Subgroups (Female)  
Week BP AML HCZ AML HCZ Gender Effect
0 SBP 164.50 ± 3.76 165.00 ± 3.71 166.50 ± 2.24 162.00 ± 3.59  
DBP 103.60 ± 1.89 104.50 ± 1.89 104.50 ± 1.57 102.50 ± 2.71  
             
1 SBP 161.50 ± 3.17 162.00 ± 3.51 163.00 ± 2.49 160.00 ± 3.33  
DBP 100.50 ± 1.17 102.00 ± 2.49 102.00 ± 1.33 100.00 ± 2.69  
             
3 SBP 158.50 ± 3.58A 157.50 ± 3.75A 161.50 ± 1.98A 156.50 ± 2.48A  
DBP 99.00 ± 0.69 A 97.50 ± 2.01A 98.00 ± 1.33A 98.00 ± 2.49A  
             
6 SBP 151.50 ± 2.99B 152.50 ± 2.81B 156.00 ± 2.21B 151.00 ± 3.15B  
DBP 90.00 ± 2.11B 94.00 ± 1.63A 93.00 ± 1.50B 92.00 ± 1.53B  
             
12 SBP 146.50 ± 2.36C 148.50 ± 2.99C 152.00 ± 1.70B 146.50 ± 2.79C 0.320NS
DBP 87.50 ± 1.54C 87.50 ± 1.17B 90.50 ± 1.17B 88.00 ± 1.53C 0.877NS
             
24 SBP 142.50 ± 2.14C 146.50 ± 3.34C 145.00 ± 2.17C 145.00 ± 3.07C  
DBP 86.50 ± 1.50B 87.00 ± 1.34B 89.50 ± 0.50C 87.50 ± 1.71C  
             
36 SBP 142.00 ± 2.00C 143.00 ± 3.59D 141.00 ± 1.94D 142.00 ± 3.82D  
DBP 86.00 ± 1.63C 87.00 ± 1.53B 88.00 ± 1.33C 86.00 ± 1.80C  
             
48 SBP 137.50 ± 2.61D 141.50 ± 3.42D 137.00 ± 2.26D 140.00 ± 3.58D  
DBP 86.00 ± 1.63C 87.00 ± 1.53B 84.50 ± 1.57D 86.00 ± 1.80C  

Significant differences within columns are indicated by ABCD (P<0.05): There are significant time-dependent reductions in BP in groups; SBP: Systolic Blood Pressure;
DBP: Diastolic Blood Pressure; AML: Amlodipine; HCZ: Hydrochlorothiazide; NS: Not Significant; (N=10 per subgroup)
Table 2: Effects of monotherapy with AML and HCZ for 48 weeks on BP (mmHg) in type 2 hypertensive diabetic subjects.